Article
Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
Cancer - 1 Feb 2020
Vysotskaia Valentina, Kaseniit K Eerik, Bucheit Leslie, Ready Kaylene, Price Kristin, Johansen Taber Katherine
Abstract excerpt
BACKGROUND: Although management guidelines exist for several genes associated with a 2-fold to 5-fold increase in the relative risk for certain cancers, the value of testing for them remains controversial. METHODS: De-identified personal and family history data for 654 individuals with pathogenic variants (PVs) in PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and/or RAD51D were analyzed for pretest and post-test...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.